Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 1510 participants.

Also called NCT02664649

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,510 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02664649
  • EudraCT 2015-001676-21
Other papers using this trial's data
  • Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy JACC. Cardiovascular interventions, 2022-09-26 DOI, PubMed 36137682
  • Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial European heart journal, 2022-08-01 DOI, PubMed 35583186 PubMed links an erratum for this paper. Erratum: PMID 35918780

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France, Germany, Italy, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02664649. Randomized; no masking; primary purpose treatment. Start 2016-08-26 (actual); primary completion 2020-10-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
Acronym
ATLANTIS
Condition
Symptomatic Aortic Stenosis
Intervention (Drug)
Apixaban
Intervention (Drug)
Standard of care
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)
Collaborator
Action Research Group (class: other)
Collaborator
Bristol-Meyers Squibb & Pfizer (class: not stated)

Record details

Record id
cardio:ct-nct02664649
Content hash
3951a54c969008c45a1cd89aebfcd4b01940d928f301148ecfaced4cdbb41668